- Home
- TOPS vs BCAB Comparison
TOPS vs BCAB Comparison
Compare TOPS & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TOPS | BCAB |
|---|---|---|
| Founded | 2000 | 2007 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.5M | 20.8M |
| IPO Year | 2004 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TOPS | BCAB |
|---|---|---|
| Price | $4.48 | $0.17 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 62.9K | ★ 1.9M |
| Earning Date | 01-01-0001 | 06-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.19 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $300,000.00 |
| Revenue This Year | $9.90 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.14 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.99 | $0.13 |
| 52 Week High | $11.47 | $1.43 |
Technical Indicators
Market Signals| Indicator | TOPS | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 37.29 | 39.81 |
| Support Level | $4.22 | $0.13 |
| Resistance Level | $6.17 | $0.27 |
| Average True Range (ATR) | 0.55 | 0.03 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 15.75 | 35.41 |
Price Performance
Historical ComparisonAbout TOPS TOP Ships Inc.
TOP Ships Inc owns tanker vessels throughout the world. The Company is an international owner and operator of modern, fuel-efficient eco tanker vessels focusing on the transportation of crude oil, petroleum products (clean and dirty), and bulk liquid chemicals. It generates revenue from the Time Charter agreements.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.